Next Show Dates Announced Sept 2 to 4, 2025
KUALA LUMPUR, Malaysia, Oct. 30, 2024 /PRNewswire/ -- Oil and Gas Asia (OGA), the largest oil, gas, energy and petrochemicals trade show in Southeast Asia, achieved unprecedented success at its recent 2024 edition with record-breaking attendance to mark its 20TH edition anniversary.
Themed "Powering Progress Towards a Sustainable Energy Landscape", the show drew 36,260 industry attendees from 72 countries, a 27% increase from last year, at the Kuala Lumpur Convention Centre from Sept 25 to 27.
The stellar performance paved the way for major opportunities and strong growth at its 2025 show from Sept 2 to 4 at the same venue.
Produced by Informa Markets, OGA provided a multi-dimensional platform for regional energy professionals, global stakeholders and thought leaders to unite and explore new solutions and diverse pathways of energy transition.
"It is extremely rewarding to deliver a show as vibrant and successful like this year. The tremendous turnout is a new benchmark. It elevated OGA to another level and cemented its leadership as the premier regional platform in the region for the energy industry. I would like to thank our Corporate Partner PETRONAS, supporting partners, sponsors, speakers, exhibitors and visitors. We are very excited to further strengthen the show in 2025 to bring more value and actively shape the energy evolution," said Mr Gerard Leeuwenburgh, Country General Manager of Informa Markets Malaysia.
This year's show featured a tripartite collaboration between OGA and the 2nd Petrochemicals Sustainability Conference (PSC) by the Malaysian Petrochemicals Association (MPA), and 7th Malaysia Oil & Gas Services Exhibition and Conference (MOGSEC) hosted by the Malaysian Oil, Gas and Energy Services Council (MOGSC).
In his opening address, Economy Minister Rafizi Ramli said: "The narrative tends to be that the days of oil and gas are numbered isn't entirely true. Any report will show you that the global energy mix in 2050 will still contain fossil fuels. Malaysia's own projections show oil and gas will still be 77% of our primary energy supply.
The OGA exhibition floor was filled by 2,000 companies and brands including industry names, sponsors and seven international pavilions from China, South Korea, Italy, India, United Kingdom, Singapore and Germany.
Exhibitors were delighted at the bustling atmosphere and streams of visitors throughout the show days.
"Excellent platform for us to meet our customers and for us to have new leads in the markets," said Mr Victor Wong, Director of Advantage Marine Services Sdn Bhd.
"OGA brings together a good amount of new products, good technologies and good people," said Mr Bjoern Sohrbeck, Director of TDL Greentech.
The two-day biennial PSC set the stage for the government launch of the Circular Economy Framework for Manufacturing Sector. The conference gathered 628 delegates and 50 regional speakers over 10 sessions with focus on decarbonisation, circular practices and balancing sustainability and business growth.
Mr Joseph Stroffolino, Director of Solution Development APAC at Air Liquide Engineering & Construction was among the delegates. "At PSC, the networking has been good. I think events like this really help to get people on the same page."
MOGSEC stamped its mark with two ministerial fireside chats on the topics of sustainable development policy framework and carbon capture in empowering Malaysia's future, and the awarding of the OGSE Innovation Awards to recognise sustainability and net-zero innovations.
Kenaga Suria Sdn Bhd took home the winner's trophy for this year's OGSE Innovation Awards with Deleum Oilfield Services Sdn Bhd in second place and Aiis Solutions Sdn Bhd in third.
MATRADE, the country's external trade promotion agency, also had a brisk time with its International Sourcing Programme (INSP) and facilitated business matching meetings between local OGSE entrepreneurs and international companies that generated RM 112,080,000.
OGA's own engagement forum, Speak OGA, featured over 20 speakers in free-toattend sessions on the show floor ranging from talks on enhancing operations, policydriven transformation for energy and emission solutions to strengthen health, safety and environment performance.
Nurturing talent took the front seat at mentoring programmes held by TalentCorp Malaysia and Society of Petroleum Engineers (SPE) KL. The Malaysia Women in Energy (MyWiE) advocacy group held a session on empowering women in the energy sector.
The outstanding turnout and collaborative spirit of OGA 2024 not only celebrated its legacy but also set the stage for a brighter, more sustainable tomorrow.
For more, visit us at www.oilandgas-asia.com.
Subscribe to our Social Media Accounts or Newsletters on OGA 2024.
Facebook: https://www.facebook.com/oilandgasasiaofficial
LinkedIn: https://www.linkedin.com/company/oil-and-gas-asia
Instagram: https://www.instagram.com/oilandgasasiaseries
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
OIL AND GAS ASIA 2024 HITS NEW HEIGHTS WITH RECORD ATTENDANCE AT 20th ANNIVERSARY EDITION
SINGAPORE, Oct. 30, 2024 /PRNewswire/ -- Teijin Limited and Hilleman Laboratories, a biotechnology company based in Singapore, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion in contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.
Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy for the development and manufacturing of cell and gene therapy products, and mutually advance CDMO business activities of respective parties.
The partnership was formed to strengthen support for Japanese customers aiming to expand into the Asia-Pacific region and to attract overseas customers from Singapore and surrounding areas to the Japanese market. Further, Teijin and Hilleman Laboratories share a vision for building a support system in Singapore for the development and manufacturing of cell and gene therapies.
In November 2023, Hilleman Laboratories launched its newest facility, a 30,000 square foot current Good Manufacturing Practice (cGMP) pilot-scale plant. Building upon this, Teijin will support Hilleman Laboratories in the establishment of a cell processing center in Singapore for cell and gene therapy. Teijin's accumulated knowledge and experience in this field will be shared with Hilleman Laboratories.
"Teijin and Hilleman Laboratories are contributing to the provision of innovative medical care through manufacturing," said Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited. "And we will build a strong cooperation system for the cell and gene therapy CDMO business to provide more desirable development and manufacturing support services to customers in the Asia-Pacific region."
Teijin group will invest in facilities and human resources to meet customer needs, with a goal of generating JPY 20 billion in regenerative medicine sales by FY 2030. The partnership with Hilleman Laboratories will help achieve this goal.
"At Hilleman Laboratories, we are driven by our mission to deliver impactful healthcare solutions" said Raman Rao, Chief Executive Officer of Hilleman Laboratories. "This partnership with Teijin marks a significant milestone in Hilleman Laboratories' journey to expand our capabilities in bioprocessing. By combining our expertise with Teijin's leadership in regenerative medicine, we are pushing the boundaries of innovation to develop cutting-edge solutions. This collaboration opens new opportunities for innovation and growth, enabling us to meet the evolving needs of the global healthcare market and positioning Singapore as a hub for the next generation of advanced therapeutic products."
Demand for CDMO services in cell and gene therapies, including regenerative medicines, is rising due to heightened technical levels in manufacturing and greater specialization in manufacturing and development functions. The fast-growing regenerative medicine market in Japan is forecast to exceed JPY 850 billion in 2030. This trend is expected to result in a greater number of regenerative medicine products that originate outside Japan. For this reason, it is vital to create a system that connects development demand within and outside Japan.
Teijin has established a comprehensive CDMO platform that provides everything from product design to industrialization for regenerative medicine products, focusing on cell and gene therapy. This platform leverages the product launch experience, technical capabilities and knowledge of Japan Tissue Engineering Co., Ltd.(J-TEC), a Teijin Group company, and the advanced research, development and production system of Teijin Regenet Co., LTD.
Hilleman Laboratories, established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD) and the Wellcome Trust, aims to make vaccines and biologics affordable in low- and middle-income countries. Hilleman Laboratories operates a dual-feature development and manufacturing hub, which provides comprehensive end-to-end biopharmaceutical product development solutions, from concept to the pilot manufacturing of clinical trial materials (CTM) for phase I and II clinical studies.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through "Human Chemistry, Human Solutions," Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in the fiscal year ending March 31, 2024.
Visit www.teijin.com.
About the Hilleman Laboratories
Hilleman Laboratories was established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD), a global research-driven pharmaceutical company, and Wellcome, a global charitable foundation dedicated to human and animal health. Hilleman Laboratories' mission is to develop affordable vaccines and biologics against infectious diseases that affect low- and middle-income countries.
The company's expertise in end-to-end product development is targeted at creating novel vaccines and biologics in areas of high unmet need as well as adapting existing vaccines and biologics with more effective delivery tools to meet challenging environments in developing countries. Hilleman Laboratories also seeks to collaborate with local, regional, and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics.
Visit www.hilleman-labs.org
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy
